Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Common Equity (2023 - 2025)

Historic Common Equity for Beta Bionics (BBNX) over the last 3 years, with Q3 2025 value amounting to $294.8 million.

  • Beta Bionics' Common Equity rose 22880.17% to $294.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $294.8 million, marking a year-over-year increase of 22880.17%. This contributed to the annual value of -$245.4 million for FY2024, which is 2080.45% down from last year.
  • As of Q3 2025, Beta Bionics' Common Equity stood at $294.8 million, which was up 22880.17% from $301.6 million recorded in Q2 2025.
  • Beta Bionics' 5-year Common Equity high stood at $313.8 million for Q1 2025, and its period low was -$245.4 million during Q4 2024.
  • In the last 3 years, Beta Bionics' Common Equity had a median value of -$208.7 million in 2023 and averaged -$25.3 million.
  • Per our database at Business Quant, Beta Bionics' Common Equity crashed by 2080.45% in 2024 and then surged by 24639.21% in 2025.
  • Beta Bionics' Common Equity (Quarter) stood at -$203.1 million in 2023, then decreased by 20.8% to -$245.4 million in 2024, then soared by 220.13% to $294.8 million in 2025.
  • Its last three reported values are $294.8 million in Q3 2025, $301.6 million for Q2 2025, and $313.8 million during Q1 2025.